Clinical Trial Update: Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia [Phase 2]

View source ↗

Summary

Phase II dose-finding study of RDEA3170 versus placebo in Japanese patients with gout or asymptomatic hyperuricemia completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• RDEA3170 (RDEA3170)

Snippet

Sponsor: AstraZeneca | Conditions: Gout and Hyperuricemia | Phase 2 | Status: COMPLETED | Results posted: 2019-09-24